spacer
home > ebr > winter 2018 > training day
PUBLICATIONS
European Biopharmaceutical Review

Training Day

As opposed to traditional pharmaceutical products, biopharmaceuticals are complex high-molecular-weight items of biological origin derived from living organisms, cells, animals or plants. Market predictions strongly suggest that sales of biopharmaceutical products will continue to increase year-on-year, with the market being driven primarily by further increases in sales of recombinant monoclonal antibodies (mAbs) that have proven to be successful therapies for a large number of disease states.

However, the focus on advanced therapy medicinal products is increasing, with some manufacturers looking to diversify into gene therapies, cell therapies and tissue engineering as strategies for pipeline development. By 2020, biopharma sales are estimated to contribute at least 50% of total biopharma and pharma revenues, with the former contributing 80% of product candidates in pipelines (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr John Milne is currently Director of training at the National Institute for Bioprocessing Research and Training. He has been employed in the biopharma industry for 20 years and has performed in a series of roles, including process development, optimisation, scale-up and GMP manufacture of therapeutic proteins and mAbs in regulated facilities. John received his PhD in molecular enzymology from the Department of Biochemistry at University College Dublin.
spacer
Dr John Milne
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Countdown to the UK’s leading production line event begins

In light of Nick Peters’, author of the Annual Manufacturing report 2018, comment that “UK manufacturing has come a long way in recent years, as we have seen from their stellar performance in 2017,” it’s no surprise that the PPMA Show is gearing up for its biggest show to date when it returns to the NEC, Birmingham, between 25-27 September 2018.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

Drug Discovery 2018

21-22 March 2018, Copthorne Tara Hotel, Scarsdale Place, Kensington, London

SMi Group is proud to announce the return of Drug Discovery in 2018. The successful conference will return for its 2nd year on the 21st and 22nd March.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement